Press release from Emotra AB (publ)

Kista, 11 March 2022

Daniel Poté to step down as president of Emotra AB

Daniel will be leaving the company this spring and the process of recruiting a new president will be initiated.

Emotra AB hereby announces that its president, Daniel Poté, will be leaving the company this spring to take on new opportunities elsewhere. Daniel will continue to support the company until a new president has been appointed and has started.

Daniel joined Emotra in 2017 as our marketing manager and was appointed president about a year later. He is responsible for our shift in strategy to depression relapse, with a focus on building alliances with researchers in Europe and the USA, as well as the planning of a clinical multi-center study.

In 2021, Emotra carried out a reverse acquisition of the American company NeuraMetrix Inc. In this transaction, Daniel led the work of creating a group structure and merging our operations with those of our subsidiary in the USA.

Claes Holmberg, chairman of the board of Emotra AB:

"Daniel Poté has carried out his duties as president of Emotra with great skill and ambition. We are very pleased with the work he has done. We greatly respect Daniel's choice to leave his position as our president to pursue new challenges and we are deeply grateful for his leadership of the company's development during his time at Emotra's helm."

Daniel Poté, Emotra AB's resigning president:

"Leading Emotra's development to where we stand today has been both challenging and rewarding. The company now has access to unique technologies in the areas mental disorders and dementia, which face vast and growing needs around the globe. The enormous market potential of this situation means that the company has an exciting journey ahead."

For further information, please contact:

Claes Holmberg, Chairman of the Board

Telephone: +46 708 - 25 45 47

E-mail::claes@emotra.se

Emotra AB (publ) is a medical technology company that carries out research, development, clinical studies and marketing in the area of neurological research mental health. The Company's methods/products, NeuraMetrix TC and EDOR®, are unique, proprietary and patent-protected.

EMOTRA AB, Färögatan 33, 164 51 Kista, Sweden

Tel: +46 732-34 41 93, www.emotra.se

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Emotra AB published this content on 16 March 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 March 2022 09:17:03 UTC.